Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

被引：0
|
作者：
Chen, Lei [1 ]
Latremouille-Viau, Dominick [2 ]
Guerin, Annie [2 ]
Nitulescu, Roy [2 ]
Gagnon-Sanschagrin, Patrick [2 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Anal Grp Inc, Montreal, PQ, Canada
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis
    Iriyama, Noriyoshi
    Sugimoto, Kei-Ji
    Sato, Eriko
    Takaku, Tomoiku
    Tokuhira, Michihide
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujita, Hiroyuki
    Kimura, Yuta
    Fujioka, Isao
    Asou, Norio
    Kizaki, Masahiro
    Komatsu, Norio
    Hatta, Yoshihiro
    Kawaguchi, Tatsuya
    BLOOD, 2018, 132
  • [12] Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
    Iriyama, Noriyoshi
    Sugimoto, Kei-Ji
    Sato, Eriko
    Takaku, Tomoiku
    Tokuhira, Michihide
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujita, Hiroyuki
    Fujioka, Isao
    Kimura, Yuta
    Asou, Norio
    Kizaki, Masahiro
    Komatsu, Norio
    Hatta, Yoshihiro
    Kawaguchi, Tatsuya
    MEDICAL ONCOLOGY, 2018, 35 (11)
  • [13] Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy
    Smith, B. Douglas
    Liu, Jun
    Latremouille-Viau, Dominick
    Zhou, Zhou
    Guerin, Annie
    Fernandez, Daniel
    Yi, Dingdong
    Wang, Xufei
    Wu, Eric Q.
    Mhatre, Shivani K.
    Keir, Christopher H.
    Chen, Lei
    BLOOD, 2014, 124 (21)
  • [14] Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand
    Kulpeng, Wantanee
    Sompitak, Sumalai
    Jootar, Saengsuree
    Chansung, Kanchana
    Teerawattananon, Yot
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 534 - 543
  • [15] Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy
    Breccia, Massimo
    Cannella, Laura
    Nanni, Mauro
    Stefanizzi, Caterina
    Alimena, Giuliana
    ACTA HAEMATOLOGICA, 2007, 118 (03) : 162 - 164
  • [16] Health-Related Quality of Life in Patients With Chronic Myeloid Leukemia Receiving First-Line Therapy With Nilotinib
    Efficace, Fabio
    Castagnetti, Fausto
    Martino, Bruno
    Breccia, Massimo
    D'Adda, Mariella
    Angelucci, Emanuele
    Stagno, Fabio
    Cottone, Francesco
    Malato, Alessandra
    Trabacchi, Elena
    Capalbo, Silvana Franca
    Gobbi, Marco
    Visani, Giuseppe
    Salvucci, Marzia
    Capodanno, Isabella
    Tosi, Patrizia
    Tiribelli, Mario
    Scortechini, Anna Rita
    Levato, Luciano
    Maino, Elena
    Binotto, Gianni
    Gugliotta, Gabriele
    Vignetti, Marco
    Baccarani, Michele
    Rosti, Gianantonio
    CANCER, 2018, 124 (10) : 2228 - 2237
  • [17] Economic Burden of Hospitalizations for Patients with Newly Diagnosed Acute Myeloid Leukemia in Remission in the United States: Retrospective Analysis of an Administrative Claims Database
    Chen, Clara
    Papademetriou, Eros
    Kiendrebeogo, Zephirin
    Potluri, Ravi
    BLOOD, 2021, 138
  • [18] Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy
    Fabio Efficace
    Fabio Stagno
    Alessandra Iurlo
    Massimo Breccia
    Francesco Cottone
    Massimiliano Bonifacio
    Elisabetta Abruzzese
    Fausto Castagnetti
    Giovanni Caocci
    Monica Crugnola
    Isabella Capodanno
    Bruno Martino
    Mario Tiribelli
    Andrea Patriarca
    Antonella Gozzini
    Patrizia Pregno
    Susanne Saussele
    Nicola Cascavilla
    Claudio Fozza
    Micaela Bergamaschi
    Gianni Binotto
    Marco Vignetti
    Gianantonio Rosti
    Leukemia, 2020, 34 : 488 - 498
  • [19] Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China
    Na Li
    Bin Zheng
    Hong-Fu Cai
    Jing Yang
    Xiao-Feng Luo
    Li-Zhu Weng
    Feng-Mei Zhan
    Mao-Bai Liu
    Clinical Drug Investigation, 2018, 38 : 79 - 86
  • [20] Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China
    Li, Na
    Zheng, Bin
    Cai, Hong-Fu
    Yang, Jing
    Luo, Xiao-Feng
    Weng, Li-Zhu
    Zhan, Feng-Mei
    Liu, Mao-Bai
    CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 79 - 86
12345